Skip to main content
USNA
NYSE Life Sciences

USANA Health Sciences Appoints Kevin Guest as CEO; Jim Brown Steps Down

Analysis by Wiseek.ai
Sentiment info
Neutral
Importance info
7
Price
$19.57
Mkt Cap
$357.756M
52W Low
$18.48
52W High
$38.32
Market data snapshot near publication time

summarizeSummary

USANA Health Sciences announced a leadership transition with Jim Brown stepping down as CEO and President, and former CEO Kevin Guest reassuming the role to drive growth and enhance shareholder value.


check_boxKey Events

  • CEO Departure

    Jim Brown has stepped down from his positions as Chief Executive Officer and President of the company.

  • CEO Re-appointment

    Kevin Guest, who previously served as CEO from 2015 to 2023 and is currently the Executive Chairman, will reassume the role of Chief Executive Officer and continue as Chairman of the Board.

  • Strategic Rationale

    The leadership transition is intended to accelerate growth and enhance shareholder value, with Mr. Guest bringing deep sales, organizational, and strategic experience.

  • Compensation Details Pending

    The material terms of compensation arrangements for both Mr. Brown's separation and Mr. Guest's new CEO role have not yet been finalized and will be disclosed in a future amendment to the 8-K.


auto_awesomeAnalysis

USANA Health Sciences announced a significant leadership transition, with Jim Brown stepping down as CEO and President. The company has appointed Kevin Guest, who previously served as CEO for eight years and is currently the Executive Chairman, to reassume the CEO role. This move is framed as a strategic decision to accelerate growth and enhance shareholder value, leveraging Mr. Guest's extensive experience and familiarity with the company's operations and sales force. Investors should monitor the upcoming disclosures regarding the compensation arrangements for both executives, as these details could provide further insights into the nature of the transition.

At the time of this filing, USNA was trading at $19.57 on NYSE in the Life Sciences sector, with a market capitalization of approximately $357.8M. The 52-week trading range was $18.48 to $38.32. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed USNA - Latest Insights

USNA
Apr 07, 2026, 4:50 PM EDT
Filing Type: DEF 14A
Importance Score:
7
USNA
Mar 16, 2026, 2:57 PM EDT
Filing Type: 10-K
Importance Score:
9
USNA
Feb 17, 2026, 8:33 PM EST
Filing Type: 8-K
Importance Score:
8
USNA
Feb 11, 2026, 4:51 PM EST
Filing Type: 8-K/A
Importance Score:
8
USNA
Jan 12, 2026, 6:29 AM EST
Filing Type: 8-K
Importance Score:
7
USNA
Jan 08, 2026, 9:01 AM EST
Filing Type: 8-K
Importance Score:
7